Novartis Suspends Production of Interceptor, Sentinel,
Program, Clomicalm and Deramaxx
medication options and changes with your pet’s doctor—even natural supplements,
over-the-counter meds and store bought flea and tick treatments. And don't miss our upcoming Raising Indiana conversation with Cathy Ball with Vectra3D regarding medications and flea/tick treatments.
Novartis closed an important manufacturing plant in
in response to consumer complaints it has received regarding a number of its
leading human consumer medications. The FDA issued a highly critical report of
that plant (see here) after an
inspection in June of last year. On January 8th, Novartis announced in a press release
that it was voluntarily recalling a number of its leading human products
produced at the plant including Excedrin, NoDoz, Bufferin and Gas-X while it
strengthens quality standards. On January 5th, Novartis sent a letter to
veterinarians informing them that it was suspending production and shipments of
the following Novartis Animal Health (NAH) brands including Interceptor Flavor
Tabs, Sentinel Flavor Tabs, Clomicalm, Program Tablets and Suspension, and
Milbemite. The letter also noted that production of Deramaxx which was just
recently moved to the
plant will also be affected although the company will continue to ship that
product from existing inventory.
suspension is leaving pet owners looking for these products subject to the
inventory on hand with their local veterinarian and with discount suppliers
such as VetDepot.com As those supplies are exhausted, veterinarians will be
obligated to prescribe competing substitutes such as Heartgard,
Trifexis, Advantage Multi, and Rimadyl.
After learning about the situation, some consumers are asking for alternatives
even when stocks are on hand. Novartis has not given an indication of when
production might resume however they have stated that the recent actions were
coordinated with the involvement of health authorities. With the FDA’s
involvement, there is the possibility that the closure could be lengthy if it
reaches the level of problems recently experienced at facilities owned by
Johnson & Johnson, Genzyme, and Hospira.